@article{JTD22668,
author = {Vasu Tumati and Puneeth Iyengar},
title = {The current state of oligometastatic and oligoprogressive non-small cell lung cancer},
journal = {Journal of Thoracic Disease},
volume = {10},
number = {Suppl 21},
year = {2018},
keywords = {},
abstract = {Oligometastatic disease is defined as an intermediate state between localized and widespread metastatic disease. Given that in the oligometastatic state gross tumors represent the full extent of disease, there may be a role for curative local therapy despite metastatic disease. As nearly 60% of patients with non-small cell lung cancer (NSCLC) present with metastatic disease and another 45% of patients with initially localized disease will ultimately develop distant metastases, NSCLC represents a prime disease for aggressive intervention. In this review, the definition, prognostic factors, patient selection, rationale and evidence for treatment of oligoprogressive and oligometastatic NSCLC is discussed, including recent prospective trials and future directions.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/22668}
}